Physician profile
Jeff D Thomas
NPI 1336131960
$4,705.11
in general payments reported to CMS, 2019-2025
14 companies · $652 in 2025
The $652 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $217 · 2021: $361 · 2022: $674 · 2023: $1,154 · 2024: $924 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,780.76 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Synergeyes Contact Lens |
| Alcon Vision LLC | $1,641.88 | 2019-2025 | Total30, Precision7, Freshlook |
| Bausch & Lomb Americas INC. | $451.18 | 2023-2025 | Infuse |
| Lkc Technologies, INC. | $161.33 | 2023 | |
| Glaukos Corporation | $159.90 | 2024-2025 | Radius, Radius Xr |
| Maculogix, INC. | $140.65 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $102.06 | 2019-2023 | Acuvue |
| Abbvie INC. | $99.31 | 2022-2023 | |
| Optos, INC. | $43.19 | 2020-2021 | |
| Lombart Brothers, INC. | $34.48 | 2023 | Opd-III |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.90 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $29.63 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.76 | 2021 | |
| Visioneering Technologies, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.